Diabetes and metabolic dysfunction-associated fatty liver disease

Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care

(2021) M. L. Morieri et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

(2021) Alessandro Mantovani et al.   Metabolites

Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: A population –based study

(2021) María Teresa Julián et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Treatments for NAFLD: State of Art

(2021) Alessandro Mantovani et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Non-alcoholic fatty liver disease

(2021) Elizabeth E Powell et al.   LANCET

Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions

(2021) Samar H. Gerges et al.   LIFE SCIENCES

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

(2021) Seong Hee Kang et al.   Clinical and Molecular Hepatology

Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis

(2021) Chanthawat Patikorn et al.   Annals of Hepatology

MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease

(2020) Mohammed Eslam et al.   GASTROENTEROLOGY

Drinking and Obesity: Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Interactions

(2020) Fredrik Åberg et al.   SEMINARS IN LIVER DISEASE

Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease

(2020) Ting Ting Chan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Temporal Trends in Cardiovascular Complications in People With or Without Type 2 Diabetes: The Fremantle Diabetes Study

(2020) Wendy A Davis et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

(2020) Mohammed Eslam et al.   JOURNAL OF HEPATOLOGY

Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies

(2020) Helen Jarvis et al.   PLOS MEDICINE

Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases

(2020) Ethan M. Weinberg et al.   Clinical Gastroenterology and Hepatology

MR elastography‐based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study

(2020) Ma Ai Thanda Han et al.   LIVER INTERNATIONAL

Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease

(2020) Jeffrey Budd et al.   Current Diabetes Reports

Liver fat quantification: where do we stand?

(2020) Jitka Starekova et al.   Abdominal Radiology

Changes in the Epidemiology of Hepatobiliary Disease Complicating Type 2 Diabetes over 25 Years: The Fremantle Diabetes Study

(2020) Timothy M.E. Davis et al.   Journal of Clinical Medicine

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2019) Stephen A Harrison et al.   LANCET

Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials

(2018) Cyrielle Caussy et al.   HEPATOLOGY

Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith–Wiedemann syndrome: an international consensus statement

(2018) Frédéric Brioude et al.   Nature Reviews Endocrinology

Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis

(2017) Guangqin Xiao et al.   HEPATOLOGY

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score)

(2017) Surasak Saokaew et al.   LIVER INTERNATIONAL

Clinical epidemiology and disease burden of nonalcoholic fatty liver disease

(2017) Brandon J Perumpail et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Subclinical Disease Burden as Assessed by Whole-Body MRI in Subjects With Prediabetes, Subjects With Diabetes, and Normal Control Subjects From the General Population: The KORA-MRI Study

(2016) Fabian Bamberg et al.   DIABETES

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016) et al.   DIABETOLOGIA

Noninvasive fatty liver markers predict liver disease mortality in the U.S. population

(2016) Aynur Unalp-Arida et al.   HEPATOLOGY

The ability of Hepascore to predict liver fibrosis in chronic liver disease: a meta-analysis

(2016) Yi Huang et al.   LIVER INTERNATIONAL

Epidemiology and natural history of non-alcoholic fatty liver disease

(2016) Yousef Fazel et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE

(2015) I. Doycheva et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Changes in Diabetes-Related Complications in the United States, 1990–2010

(2014) Edward W. Gregg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials

(2013) Mazen Noureddin et al.   HEPATOLOGY

Prevalence, Incidence, and Prognosis of Hepatobiliary Disease in Community-Based Patients with Type 2 Diabetes: The Fremantle Diabetes Study

(2012) Timothy M. E. Davis et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease

(2011) Leon A Adams et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy

(2011) Scott B. Reeder et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

A simple index of lipid overaccumulation is a good marker of liver steatosis

(2010) Giorgio Bedogni et al.   BMC GASTROENTEROLOGY

Physicians’ attitudes and adherence to use of risk scores for primary prevention of cardiovascular disease: cross-sectional survey in three world regions

(2009) Andrei C. Sposito et al.   CURRENT MEDICAL RESEARCH AND OPINION

Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease

(2009) Jeong-Hoon Lee et al.   DIGESTIVE AND LIVER DISEASE

Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors

(2009) Anna Kotronen et al.   GASTROENTEROLOGY

Improved survival in both men and women with diabetes between 1980 and 2004 – a cohort study in Sweden

(2008) Mats Eliasson et al.   Cardiovascular Diabetology

Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis

(2008) Gunda Millonig et al.   HEPATOLOGY